$TTI.V

2 stories mentioning TTI.VUpdated just now

Every FINWIRES story that references TTI.V, newest first.

Thiogenesis Therapeutics Appoints Gilad Aharon to its Board

Thiogenesis Therapeutics (TTI.V) on Wednesday said it appointed of Gilad Aharon to its board of directors.Aharon is a co-founder and portfolio manager at Rosalind Advisors, a Toronto-based life-sciences institutional investor.The appointment follows Rosalind Advisors' investment in Thiogenesis' recently completed, non-brokered private placement."Gil brings significant experience and depth of insight in the life sciences sector, and we look forward to working together in advancing TTI-0102," said chief executive Patrice Rioux.The company's shares were last seen unchanged at $0.57 on the TSX Venture Exchange.

$TTI.V

Mining & Metals37d ago

Thiogenesis Therapeutics to Raise $8 Million Via a Non-Brokered Private Placement

Thiogenesis Therapeutics (TTI.V) on Monday said it will raise up to $8 million in a non-brokered private placement of shares.The company will place up to 16-million shares priced at $0.50 apiece.The company expects to close the offering by the end of May subject to receipt of all necessary regulatory approvals.Proceeds will be used to support the clinical development of TTI-0102, including an investigator-initiated study in cystinosis and a Phase 2 clinical study in Leigh syndrome, together with formulation and manufacturing activities, regulatory engagement, and general working capital and corporate needs.The company's shares last traded May 8, closing at $0.56 on the TSX Venture Exchange.

$TTI.V

Track with the FINWIRES app suite

FolioX

Track TTI.V in your portfolio

WheelAI

Analyze TTI.V options with the wheel strategy

StockInsider

See market sentiment on TTI.V